- Home
- GSL vs NEO Comparison
GSL vs NEO Comparison
Compare GSL & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSL
- NEO
- Stock Information
- Founded
- GSL 2007
- NEO 2001
- Country
- GSL Greece
- NEO United States
- Employees
- GSL N/A
- NEO N/A
- Industry
- GSL Marine Transportation
- NEO Precision Instruments
- Sector
- GSL Consumer Discretionary
- NEO Health Care
- Exchange
- GSL Nasdaq
- NEO Nasdaq
- Market Cap
- GSL 945.2M
- NEO 902.1M
- IPO Year
- GSL 2006
- NEO 1999
- Fundamental
- Price
- GSL $27.95
- NEO $7.25
- Analyst Decision
- GSL Strong Buy
- NEO Buy
- Analyst Count
- GSL 1
- NEO 9
- Target Price
- GSL $30.00
- NEO $13.31
- AVG Volume (30 Days)
- GSL 342.4K
- NEO 2.1M
- Earning Date
- GSL 08-04-2025
- NEO 07-29-2025
- Dividend Yield
- GSL 7.53%
- NEO N/A
- EPS Growth
- GSL 20.64
- NEO N/A
- EPS
- GSL 10.54
- NEO N/A
- Revenue
- GSL $715,232,000.00
- NEO $672,361,000.00
- Revenue This Year
- GSL $3.22
- NEO $13.97
- Revenue Next Year
- GSL N/A
- NEO $11.36
- P/E Ratio
- GSL $2.62
- NEO N/A
- Revenue Growth
- GSL 3.83
- NEO 10.10
- 52 Week Low
- GSL $17.73
- NEO $6.08
- 52 Week High
- GSL $28.08
- NEO $19.12
- Technical
- Relative Strength Index (RSI)
- GSL 69.67
- NEO 45.74
- Support Level
- GSL $26.80
- NEO $7.20
- Resistance Level
- GSL $27.60
- NEO $7.82
- Average True Range (ATR)
- GSL 0.57
- NEO 0.34
- MACD
- GSL 0.06
- NEO 0.05
- Stochastic Oscillator
- GSL 99.61
- NEO 41.24
About GSL Global Ship Lease Inc New
Global Ship Lease Inc operates in the container shipping industry. The company owns and charters out containerships under long-term, fixed-rate charters to container liner companies. The majority of the company's revenues are derived from charters to MAERSK. Its fleet consisted of more than 60 containerships.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.